GlassScriptPhysician profile
Christine Vu
NPI 1962907808
$1,631.97
in general payments reported to CMS, 2019-2025
14 companies · $529 in 2025
The $529 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.74 · 2021: $109 · 2022: $378 · 2023: $240 · 2024: $355 · 2025: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,123.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $380.51 | 2019-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $242.77 | 2022-2024 | Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $177.52 | 2022-2024 | Zepbound, Mounjaro |
| Intra-Sana Laboratories | $173.66 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.06 | 2022-2024 | Jardiance |
| Nova Eye, INC. | $125.00 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $115.00 | 2023 | |
| Merck Sharp & Dohme LLC | $67.84 | 2024 | |
| Novo Nordisk INC | $52.14 | 2024 | Wegovy |
| Pfizer INC. | $34.91 | 2022-2025 | |
| Dexcom, INC. | $34.38 | 2025 | Dexcom G6 Transmitter |
| Livanova USA, INC. | $30.33 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Takeda Pharmaceuticals U.S.A., INC. | $27.04 | 2025 | Cuvitru |
| Amgen INC. | $21.81 | 2025 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.